DEASY MAFAZADARA (2015) STUDI PENGGUNAAN EPOETIN ALFA DAN EPOETIN BETA PADA PASIEN PENYAKIT GINJAL KRONIK YANG MENJALANI HEMODIALISIS (Penelitian dilakukan di Instalasi Hemodialisis RSUD Dr. Soetomo Surabaya. Skripsi thesis, UNIVERSITAS AIRLANGGA.

	Text 1. HALAMAN JUDUL .pdf Download (226kB)
	Text 2. ABSTRAK .pdf Download (217kB)
	Text 3. DAFTAR ISI .pdf Download (302kB)
	Text 4. BAB 1.pdf Restricted to Registered users only until 26 May 2023. Download (265kB) | Request a copy
	Text 5. BAB 2.pdf Restricted to Registered users only until 26 May 2023. Download (1MB) | Request a copy
	Text 6. BAB 3.pdf Restricted to Registered users only until 26 May 2023. Download (453kB) | Request a copy
	Text 7. BAB 4.pdf Restricted to Registered users only until 16 May 2023. Download (252kB) | Request a copy
	Text 8. BAB 5.pdf Restricted to Registered users only until 26 May 2023. Download (773kB) | Request a copy
	Text 9. BAB 6.pdf Restricted to Registered users only until 26 May 2023. Download (358kB) | Request a copy
	Text 10. BAB 7.pdf Restricted to Registered users only until 26 May 2023. Download (346kB) | Request a copy
	Text 11. DAFTAR PUSTAKA.pdf Download (336kB)
	Text 12. LAMPIRAN.pdf Restricted to Registered users only until 26 May 2023. Download (464kB) | Request a copy

Abstract

BACKGROUND: Erythropoietin (EPO) is a glycoprotein hormone which controls production of red blood cell precursor. The decrease of EPO is the main cause of anemia in patients with chronic kidney disease (CKD). Erythropoiesis stimulating agents (ESAs) therapy is the first step in handling anemia in patients with CKD to substitute the lack of erythropoietin. There are several recombinant human EPO as epoetin alpha and beta. During the therapy, there are some factors influencing the process of erythropoesis and the efficacy of EPO therapy including uremic condition, infection-inflamation, oedema, and Ca x P level. OBJECTIVE: The aim of the study was to describe the use of epoetin alpha and beta including the type, dose, route, influencing factor of EPO efficacy and possibility of drug related problem (DRP). SUBJECTS AND METHODS: It was an observational study conducted in Hemodialysis Installation of Dr. Soetomo Teaching Hospital Surabaya during March to May 2015. The study has been approved by ethic committee. Criteria of inclusions of subject were patient who underwent therapy of epoetin alpha or beta, with data of Hb, SI, TIBC, Ca x P, BUN, leukocytes, weight, blood pressure, body temperature, and vascular access. RESULTS: Total sample obtained in this study were 27 patients. The type of epoetin used were epoetin alpha (51,85%), and epoetin beta (48,15%). The dose of epoetin alpha and beta received by patients were 3000 IU and 2000 IU respectively without calculating dose individually. All patients received underdose of epoetin alpha and beta. The route of therapy were SC (96,30%), and IV (3.70%). From this study, it could be observed that patients with high uremic condition had low average of Hb. Analysis of factors that affecting Hb include uremia conditions, levels of Ca x P, and edema can not be analyzed because the data less representative. Side effects that might be happened during the therapy were headache and cough.

Actions (login required)

View Item